Cover Image
市場調查報告書

RaQualia Pharma Inc. : 產品平台分析

RaQualia Pharma Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 203738
出版日期 內容資訊 英文 43 Pages
訂單完成後即時交付
價格
Back to Top
RaQualia Pharma Inc. : 產品平台分析 RaQualia Pharma Inc. - Product Pipeline Review - 2016
出版日期: 2016年07月30日 內容資訊: 英文 43 Pages
簡介

RaQualia Pharma Inc. 是以東京為據點,進行臨床及前臨床候補藥物之藥物研發·開發·商品化的全球性發展製藥公司。其產品中有胃不全麻痺,慢性便秘,神經性疼痛,伴隨癌症的食慾不振,慢性發炎性疼痛,急性痛,過敏,老年癡呆症等的治療藥。

本報告提供RaQualia Pharma Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,後期階段及中止的計劃等相關資訊。

RaQualia Pharma Inc.的基本資料

RaQualia Pharma Inc.概要

  • 主要資訊
  • 企業資料

RaQualia Pharma Inc.:R&D概要

  • 主要的治療範圍

RaQualia Pharma Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

RaQualia Pharma Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第Ⅲ相的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

RaQualia Pharma Inc.:藥物簡介

  • RQ-00000004
  • RQ-00000010
  • RQ-00000774
  • RQ-00201894
  • RQ-00202730
  • RQ-00203066
  • RQ-00310941
  • RQ-00432933
  • 神經性疼痛用Cav3.2 抑制劑
  • 疼痛用Nav1.7 鈉·流通管道抑制劑
  • 疼痛用Nav1.8 鈉·流通管道抑制劑
  • 神經性疼痛用TRPM8 抑制劑
  • 未公佈的針對症狀特殊離子·流通管道調整藥
  • 疼痛用特殊離子·流通管道調整藥

RaQualia Pharma Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

RaQualia Pharma Inc.:最近的開發平台趨勢

RaQualia Pharma Inc.:暫停中的計劃

RaQualia Pharma Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08109CDB

Summary

Global Markets Direct's, 'RaQualia Pharma Inc. - Product Pipeline Review - 2016', provides an overview of the RaQualia Pharma Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by RaQualia Pharma Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of RaQualia Pharma Inc.
  • The report provides overview of RaQualia Pharma Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses RaQualia Pharma Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features RaQualia Pharma Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate RaQualia Pharma Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for RaQualia Pharma Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding RaQualia Pharma Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • RaQualia Pharma Inc. Snapshot
    • RaQualia Pharma Inc. Overview
    • Key Information
    • Key Facts
  • RaQualia Pharma Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • RaQualia Pharma Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • RaQualia Pharma Inc. - Pipeline Products Glance
    • RaQualia Pharma Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • RaQualia Pharma Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • RaQualia Pharma Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • RaQualia Pharma Inc. - Drug Profiles
    • tegoprazan
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00000010
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00310941
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00000774
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00201894
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00202730
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00203066
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00203078
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00433412
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Block Cav3.2 for Neuropathic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block Nav1.7 Sodium Channel for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block Nav1.8 Sodium Channel for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00434739
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • RaQualia Pharma Inc. - Pipeline Analysis
    • RaQualia Pharma Inc. - Pipeline Products by Target
    • RaQualia Pharma Inc. - Pipeline Products by Route of Administration
    • RaQualia Pharma Inc. - Pipeline Products by Molecule Type
    • RaQualia Pharma Inc. - Pipeline Products by Mechanism of Action
  • RaQualia Pharma Inc. - Recent Pipeline Updates
  • RaQualia Pharma Inc. - Dormant Projects
  • RaQualia Pharma Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • RaQualia Pharma Inc., Key Information
  • RaQualia Pharma Inc., Key Facts
  • RaQualia Pharma Inc. - Pipeline by Indication, 2016
  • RaQualia Pharma Inc. - Pipeline by Stage of Development, 2016
  • RaQualia Pharma Inc. - Monotherapy Products in Pipeline, 2016
  • RaQualia Pharma Inc. - Phase III, 2016
  • RaQualia Pharma Inc. - Phase I, 2016
  • RaQualia Pharma Inc. - Preclinical, 2016
  • RaQualia Pharma Inc. - Discovery, 2016
  • RaQualia Pharma Inc. - Pipeline by Target, 2016
  • RaQualia Pharma Inc. - Pipeline by Route of Administration, 2016
  • RaQualia Pharma Inc. - Pipeline by Molecule Type, 2016
  • RaQualia Pharma Inc. - Pipeline Products by Mechanism of Action, 2016
  • RaQualia Pharma Inc. - Recent Pipeline Updates, 2016
  • RaQualia Pharma Inc. - Dormant Developmental Projects,2016
  • RaQualia Pharma Inc., Other Locations
  • RaQualia Pharma Inc., Subsidiaries

List of Figures

  • RaQualia Pharma Inc. - Pipeline by Top 10 Indication, 2016
  • RaQualia Pharma Inc. - Pipeline by Stage of Development, 2016
  • RaQualia Pharma Inc. - Monotherapy Products in Pipeline, 2016
  • RaQualia Pharma Inc. - Pipeline by Top 10 Target, 2016
  • RaQualia Pharma Inc. - Pipeline by Route of Administration, 2016
  • RaQualia Pharma Inc. - Pipeline by Molecule Type, 2016
  • RaQualia Pharma Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top